Cold Atmospheric Plasma Device for Pediatric Molluscum and Verruca

• Status: Not yet recruiting
• Trial end date: 2021-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is going to test a cold atmospheric plasma device (CAP), in particular a floating electrode-dielectric barrier device (FE-DBD), to treat warts and molluscum. The treatment device in this study generates cold atmospheric plasma (gaseous ionized molecules) to rid the virus from the body. Based on the successes of previous dermatologic studies, FE-DBD is being tested for this study to treat warts and molluscum. Patients will be enrolled to test the efficacy and safety of this device. The duration of the study is 4-12 weeks depending on treatment clearance. The number of lesions will be chosen by the dermatologist. Patients will receive standard of care therapy and/or NTAP depending on the number of lesions.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Medical University of South Carolina
• Collaborator: Columbia University
• Treatments: Cantharidin

Criteria

Inclusion Criteria:

• All patients from 4-21 years old with at least 1 lesion of either verruca vulgaris or molluscum contagiosum

• Willingness of the participant and their guardian to provide consent when applicable

Exclusion Criteria:

• Unwillingness to participate in the study

• Received any treatment on the lesion in the past month, as determined by review of participant medical record

• Immunodeficiency as determined by review of participant medical record

• Adverse response to prior treatments as determined by review of medical record

• Signs of self-resolution as determined by study team members

• Conditions that lead to excessive scarring as determined by study team members

• Facial and genital lesions as determined by study team members